IPCA LABORATORIES
|
IPCA LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 21.57 | 18.58 | 34.85 | 89.87 | 47.99 |
| CEPS(Rs) | 34.94 | 29.70 | 45.07 | 53.53 | 32.21 |
| DPS(Rs) | 4.00 | 4.00 | 4.00 | 8.00 | 5.00 |
| Book NAV/Share(Rs) | 249.53 | 230.27 | 215.41 | 370.65 | 286.15 |
| Tax Rate(%) | 37.20 | 33.99 | 19.79 | 17.29 | 18.32 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 16.41 | 14.47 | 21.57 | 27.33 | 19.16 |
| EBIT Margin(%) | 12.76 | 12.71 | 19.67 | 25.85 | 16.32 |
| Pre Tax Margin(%) | 10.94 | 11.94 | 19.48 | 25.63 | 15.89 |
| PAT Margin (%) | 6.87 | 7.88 | 15.63 | 21.20 | 12.98 |
| Cash Profit Margin (%) | 11.50 | 12.07 | 19.61 | 25.06 | 17.51 |
| Performance Ratios | |||||
| ROA(%) | 5.37 | 6.06 | 13.31 | 20.29 | 12.31 |
| ROE(%) | 8.70 | 8.70 | 17.92 | 27.63 | 17.92 |
| ROCE(%) | 13.10 | 11.71 | 20.46 | 30.92 | 19.71 |
| Asset Turnover(x) | 0.78 | 0.77 | 0.85 | 0.96 | 0.95 |
| Sales/Fixed Asset(x) | 1.35 | 1.54 | 1.68 | 1.75 | 1.65 |
| Working Capital/Sales(x) | 2.42 | 1.85 | 1.96 | 2.38 | 3.04 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.74 | 0.65 | 0.60 | 0.57 | 0.60 |
| Receivable days | 63.37 | 55.52 | 53.92 | 57.48 | 61.90 |
| Inventory Days | 99.83 | 105.25 | 108.09 | 98.25 | 94.05 |
| Payable days | 100.50 | 86.04 | 111.16 | 136.39 | 128.13 |
| Valuation Parameters | |||||
| PER(x) | 57.39 | 43.62 | 30.45 | 10.59 | 14.46 |
| PCE(x) | 35.44 | 27.28 | 23.55 | 17.77 | 21.54 |
| Price/Book(x) | 4.96 | 3.52 | 4.93 | 5.13 | 4.85 |
| Yield(%) | 0.32 | 0.49 | 0.38 | 0.42 | 0.36 |
| EV/Net Sales(x) | 4.24 | 3.25 | 4.67 | 4.45 | 3.86 |
| EV/Core EBITDA(x) | 22.44 | 19.11 | 19.63 | 14.92 | 18.26 |
| EV/EBIT(x) | 33.05 | 25.41 | 23.60 | 17.14 | 23.51 |
| EV/CE(x) | 4.21 | 2.76 | 4.33 | 3.96 | 3.39 |
| M Cap / Sales | 4.10 | 3.31 | 4.64 | 4.47 | 3.80 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 23.50 | 7.03 | 7.45 | 16.80 | 23.32 |
| Core EBITDA Growth(%) | 37.28 | -23.51 | -14.35 | 64.84 | 29.76 |
| EBIT Growth(%) | 23.94 | -30.82 | -18.15 | 84.70 | 33.40 |
| PAT Growth(%) | 7.58 | -46.00 | -20.71 | 90.34 | 36.48 |
| EPS Growth(%) | 16.13 | -46.69 | -61.22 | 87.28 | 36.07 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.22 | 0.25 | 0.14 | 0.05 | 0.13 |
| Current Ratio(x) | 2.35 | 2.87 | 3.03 | 2.96 | 2.15 |
| Quick Ratio(x) | 1.30 | 1.91 | 1.77 | 1.59 | 1.16 |
| Interest Cover(x) | 6.99 | 16.47 | 102.40 | 114.20 | 38.37 |
| Total Debt/Mcap(x) | 0.04 | 0.07 | 0.03 | 0.01 | 0.03 |
Compare Financial Ratios of peers of IPCA LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| IPCA LABORATORIES | ₹40,423.3 Cr | -0% | 1.8% | 48.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹441,838.0 Cr | 1% | 4.6% | 47.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,107.0 Cr | 1% | -3.2% | 59.3% | Stock Analytics | |
| CIPLA | ₹120,270.0 Cr | -1.1% | -0.3% | 20.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹113,077.0 Cr | 2.2% | 12.1% | 21.6% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,553.2 Cr | -2.7% | 0.8% | 43.8% | Stock Analytics | |
IPCA LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| IPCA LABORATORIES | -0% |
1.8% |
48.7% |
| SENSEX | -2.1% |
-2% |
11.3% |
You may also like the below Video Courses
